Published: 2018-03-21

Renin angiotensin system and pulmonary hemodynamics in chronic obstructive pulmonary disease

Preeti Chauhan, Rajesh Chetiwal


Background: Pulmonary hypertension in chronic obstructive pulmonary disease (COPD) due to chronic alveolar hypoxia is probably the main contributor to the pathogenesis of pulmonary hypertension in COPD.  Angiotensin II is a potent vasoconstrictor in renin angiotensin aldosterone system (RAAS), it has been shown to promote growth response in vascular smooth muscle cell contributing towards pulmonary hypertension. So, the Echocardiographicaliy measured MPAP and its correlation with RAAS in patients of COPD was evaluated.

Methods: A prospective observational study was done in 32 patients with COPD and 10 age matched healthy, non-smoker subject included as controls. Stable patients requiring no change in their medication in the previous four weeks and not having had an acute exacerbation in that period were included. MPAP was calculated. Measurement of Ang II and aldosterone was done.

Results: Thirty-two cases of COPD, meeting inclusion criteria were enrolled comprising of 32 males and the mean age of patients ±2sd was (55.6 ±16.8), while mean age of controls ± 2sd was 49.60 ±5.56. Arterial blood gas analysis, PaO2 was ranged from (mean±2sd 75.44±12.1), PaCo2 ranged from (mean ±2sd 41.36±3.79) and SpO2 ranged from (mean±2sd 94.03 2±.74). Mean ±2sd of plasma Ang II in COPD cases was (4.9±3.8) ng/dl, significantly higher in comparison with controls (p < 0.001). Mean ±2sd of plasma ACE activity was (51.12±26.9) in COPD. Mean ±2sd of plasma aldosterone was (182.35±364.2) in COPD cases with significant (p<0.01). The MPAP in COPD cases was (mean±2sd 34.53±7.70).

Conclusions: Use of Doppler has the advantage of being noninvasive and has been shown to be extremely reproducible in evaluation of MPAP and CO. The increased level of Ang II with increase MPAP in the present study would suggest that this may be a suitable model for investigating effects of novel vasodilator drugs for the treatment of pulmonary hypertension developed due to COPD.


Aldosterone, Angiotensin, COPD, Pulmonary hypertension, Renin

Full Text:



Cooper R, Ghali J, Simmons BE, Castaner A. Elevated pulmoanary artery pressure. An independent predictor of mortality. Chest 1991;99(1):112-20.

Pride NB, Burrows B. Development of impaired lung function. Natural history and risk factors. In chronic obstructive pulmonary disease. Springer, Boston;1996:69-91

Weitzenblum E, Chaouat A, Oswald MS. Pulmonary hypertension due to chronic hypoxic lung disease. In pulmonary circulation.1996;156-70.

Heath D. Remodelling of the pulmonary vasculature in hypoxic lung disease. In pulmonary circulation.1996;171-9.

Burrows B, Kettel LJ, Niden AH, Rabinowitz M, Diener CF. Patterns of cardiovascular dysfunction in chronic obstructive lung disease. N Engl J Med. 1972;286(17):912-8.

Wright JL, Levy RD, Churg A. Pulmonary hypertension in chronic obstructive pulmonary disease: current theories of pathogenesis and their implication for treatment. Thorax. 2005;60:605-9.

Wilkinson M, Langhorne CA, Heath D, Barer GR, Howard P. A pathophysiological study of 10 cases of hypoxic cor pulmonale. QJM: Int J Med. 1988 Jan;66(1):65-85.

Morell NW, Morris KG, Stenmark KR. Role of angiotensin converting enzyme and angiotensin II in development of hypoxic pulmonary hypertension. Am J Physiol. 1995;269:H1186-1194.

lipworth BJ, Dagg KD. Vasocostriction effects of Angiotensin II on the pulmonary vascular bed. Chest. 1994;105:1360-4.

Fernandez LA, Twickler J, Meal A. Neo-vascularization produced by Angiotensin II. J Lab Clin Med. 1985;105:141-6.

Buttery JE, Staurt S. Assessment and optimimization of kinetic methods for Angiotensin –converting enzyme in plasma. Clin Chem. 1993;39:312-6.

Berkov S. Hypoxic pulmonary vasoconstriction in the rat: the necessary role of Angiotensin II. Circ Res. 1974;35:256-61.

Zakheim RM, Mattioli L, Molteni A, Mullis KB, Bartley J. Prevention of pulmonary vascular changes of chronic alveolar hypoxia by inhibition of Angiotensin I converting enzyme in rat. Lab Invest. 1975;35:57-61.

Ives H, Benoit R, Francois K, Dominique B, Guiti Malekzadeh M et al. Endogenous angitensin II in the regulation of hypoxic pulmonary vasoconstriction in anesthetized dogs. Crit Care 2004;8:R163-R171.

Motwani JG, Struthers AD. Dose response study on the redistribution of intravascular volume by Angiotensin II in man. Clin Sci. 1992;82:397-405.

lipworth Brian J, Dagg Kenneth D. Vasoconstrictor effects of Angiotensin II on the pulmonary vascular bed. Chest. 1994;105:1360-64.

Ryan US, Ryan JW, Whitaker C, Chiu A. Localization of Angiotensin converting enzyme (kininase II): Immunocytochemistry and immuno-fluroescence. Tissue Cell. 1976;7:125-45.

Rigat B, Hubert C, Alhenc-Gelas F, Cambien F, Corrol P and Soubrier F. An insertion/ deletion polymorphism in the Angiotensin converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest. 1990;86:1343-6.

Edmund AW, Wulfie friedlander Eric D, Bateman, Kirch RE. Serum Angiotensin converting enzyme activity concentration and specific activity in granulomatous interstitial lung disease, Tuberculosis and COPD. Chest. 1995;107:706-10.

Cargill RI, Lipworth BJ. Lisinoprill attenuates acute hypoxic pulmonary vasoconstrictions in humans. Chest 1996;109:424-29.

Prewitt RL, Leffler CW. Feline hypoxic pulmonary vasoconstriction is not blocked by angitensin I converting enzyme inhibitor captopril. J Cardivas Pharmacol 1981;3:293-98.

Pison CM, Nolf JE, Levy PA, Dubois F, Brambilla CG, Paramella B. Effect of captopril combined with oxygen therapy at rest and on exercise in patients with chronic bronchitis and pulmonary hypertension. Respiration. 1991;58(1):9-14.

Zielinski J, Hawrylkicwjcz I, Gorecka D, Gluskowski J, Koscinska M. captopril effects on pulmonary and systemic hemodynamics in chronic cor pulmonale. Chest. 1986;90(4):562-5.

Nong Z, Stassen JM, Moons L, Collen D, Jansssens S. Inhibition of tissue angiotensin-converting enzyme with quinapril reduces hypoxic pulmonary hypertension and pulmonary vascular remodelling. Circulation. 1996;94(8):1941-7.

Patakas D, Georgopoulos D, Rodini H, Christaki P. Effects of captopril in patients in patients with chronic obstructive pulmaonary disease and secondary pulmonary hypertension. Postgrad Med J. 1988;64(749):193-5.

Laaban JP, Diebold B, Zellinski R, Lafay M, Raffoul H, Rochemaure J. Noninvasive estimation of systolic pulmonary artery pressure using Doppler echocardiography in patients with chronic obstructive pulmoanary disease. Chest. 1989;96(6):1258-62.